news
Highly potent antiviral against dengue could prevent spread of virus
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
List view / Grid view
Janssen Pharmaceuticals
podcast
Episode 1 – Dr Sri Gopal, Janssen Pharmaceuticals
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
article
Promising targets for deafness drug discovery
In this article, Janssen Pharmaceuticals’ Global Head of Discovery Neuroscience discusses the findings of their recent study which highlighted new roles for two gene products involved in human deafness which could enable drug discovery for some prevalent auditory disorders.
news
UK Artificial Intelligence firm signs license with Janssen for drug candidate
9 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BenevolentAI, a British artificial intelligence company has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen...
news
‘Library’ of de-prioritised pharma compounds available for researchers
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
news
Johnson & Johnson Innovation launches JLINX
16 March 2016 | By Victoria White
JLINX is designed to catalyse scientific innovations by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem...
news
Janssen and Bavarian Nordic team up for HPV infection vaccine
21 December 2015 | By Victoria White
Their goal is to develop a therapeutic vaccine which aims to intercept HPV infection-related disease, particularly in those who are diagnosed with HPV early, by enhancing the ability of the immune system to treat chronic infections and prevent progression to cancer...
news
Cypralis collaborates with Janssen on cyclophilin inhibitors
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...
news
UbiVac and Janssen to develop vaccine to intercept oral cancer
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
news
Protectimmun and ICL team up for preclinical asthma research
28 September 2015 | By Victoria White
The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research with a drug candidate in a proof-of-concept disease model of allergic asthma...
news
Major advance towards long-lasting universal influenza vaccine
25 August 2015 | By Victoria White
Scientists from The Scripps Research Institute (TSRI) and Janssen have found a way to induce antibodies to fight a wide range of influenza subtypes...
news
Janssen and Achillion enter into worldwide collaboration to combat Hepatitis C
22 May 2015 | By Victoria White
Achillion and Janssen have entered into a worldwide license and collaboration arrangement to develop and commercialise one or more of Achillion's HCV assets...
news
Janssen announces license agreement with Vertex to develop novel treatment for influenza A
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787...
news
Janssen announces expanded collaboration with International Partnership for Microbicides for development and commercialization of dapivirine
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
news
Johnson & Johnson announces new collaboration with Stop TB Partnership’s Global Drug Facility to enhance access to Anti-TB Compound
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
